Pros and cons of different therapeutic antibody formats for recombinant antivenom development
Loading...
Date
Authors
Laustsen, Andreas Hougaard
Gutiérrez, José María
Knudsen, Cecilie
Johansen, Kristoffer H.
Bermúdez Méndez, Erick
Cerni, Felipe A.
Jürgensen, Jonas A.
Ledsgaard, Line
Martos Esteban, Andrea
Øhlenschlæger, Mia
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many
advances in immunology, synthetic biology, and antibody research, different approaches and antibody
formats are being investigated for the ability to neutralize animal toxins. These different molecular
formats each have their own therapeutic characteristics. In this review, we provide an overview of the
advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks
of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic
features, propensity to cause adverse reactions, formulation, and expression for research and development
(R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the
use of human antibody formats as well as camelid heavy-domain antibody fragments due to their
compatibility with the human immune system, beneficial therapeutic properties, and the ability to
manufacture these molecules cost-effectively.
Description
Keywords
Antivenom, Venom, Recombinant antivenom, Antibodies, Snakebite, Scorpion sting, Spider bite, Animal envenoming, Pharmacokinetics, Pharmacodynamics, Immunogenicity, Venom neutralization, Antibody expression, Antivenom design, Adverse reactions, Neglected tropical diseases, Biotechnology, 615.946 Venenos animales
Citation
https://www.sciencedirect.com/science/article/pii/S0041010118301144?via%3Dihub